Background: Prednisolone (PSL) has been suggested to be useful for the treatment of Kawasaki disease (KD) resistant to i.v. immunoglobulin (IVIG), but much remains to be elucidated regarding its use. Methods: A total of 1087 subjects were involved in a two-study multicenter prospective investigation of the effects of acute phase therapy on IVIG-resistant KD. Subjects resistant to the first dose of IVIG were classified into high (≥10 mg/dL) and low (<10 mg/dL) serum C-reactive protein (CRP) groups after the first dose of IVIG.
Kawasaki disease (KD) is a common disorder in children. It is caused by systemic vasculitis with unknown etiology. 1 The clinical course is usually self-limiting and most patients recover without any sequelae, but some patients develop complications, among which giant aneurysm of the coronary artery is the most serious and potentially fatal. Much effort has been put into reducing the incidence of coronary artery lesions (CAL) including aneurysms by improving the efficacy of therapy.
I.v. immunoglobulin (IVIG) is now widely accepted as the first-line therapy for KD, 2, 3 but approximately 20% of patients are resistant to IVIG. Although an additional IVIG dose is often chosen for the treatment of KD patients resistant to the first IVIG treatment, 4 its efficacy is reported to be lower than that of the first IVIG dose. [5] [6] [7] Thus, it is clear that some KD patients cannot be treated successfully by IVIG alone, even if it is used repeatedly. Also, the incidence of CAL increases in patients treated with multiple doses of IVIG. 6, 7 Currently, prednisolone (PSL) is used for the treatment of IVIG-resistant KD, [8] [9] [10] but the optimal use of PSL for maximum effect and safety has not yet been elucidated. Here, we report the results of two large-scale, consecutive, prospective, multicenter studies to elucidate the usefulness of PSL in the treatment of IVIG-resistant KD.
Methods

Subjects
Subjects who were referred to the institutes participating in the Shizuoka Kawasaki disease Study Group (SKDS) and met the diagnostic criteria of KD were enrolled in this study. SKDS was founded by 12 hospitals in the Shizuoka prefecture in order to carry out a multicenter prospective study on acute phase therapy for KD. Subjects were treated according to a common protocol of SKDS if informed consent was obtained from parents of the patients. The first study was performed  between 1 April 2005 and 30 June 2011, and the second  between 1 August 2011 and 30 June 2015. Both studies were reviewed and accepted by the ethics committee of Shizuoka Children's Hospital. The second study was also registered as a clinical trial at UMIN (UMIN000012741).
Criteria for diagnosis and CAL
Kawasaki disease was diagnosed according to the following criteria: (i) fever persisting ≥5 days; (ii) bilateral conjunctive congestion; (iii) changes in lips and oral cavity; (iv) polymorphous exanthema; (v) changes in peripheral extremities; and (vi) acute non-purulent cervical lymphadenopathy. 11 In this study, subjects were limited to those who met ≥five diagnostic criteria.
During the study, subjects were examined for CAL on 2-D echocardiography at the time of diagnosis; 2 or 3 days after diagnosis; and then once or twice per week during hospitalization. CAL was defined as internal luminal diameter ≥3 mm in a child <5 years of age and ≥4 mm in a child ≥5 years of age. Persistent CAL was defined coronary artery dilatation or aneurysm persisting >1 month after onset.
Protocol
The protocol for the first study was designed to estimate the efficacy of the second IVIG dose (2 g/kg) in patients resistant to the first (2 g/kg; Fig. 1 ). All patients who failed to respond to the first dose of IVIG were given a second dose. Another purpose of this protocol was to estimate the efficacy of PSL (2 mg/kg) or plasma exchange (PEX), 12 used as third-line therapy in patients resistant to two consecutive IVIG doses. Third-line treatment was classified according to the following criteria: (i) effectiveness and safety already shown in a considerable number of studies; (ii) preference for use by the SKDS members; and (iii) not used in the first and the second steps. Members were allowed to choose any treatment that fulfilled all three criteria.
The regimen for PSL consisted of i.v. treatment 2 mg/kg/ day in three divided doses until fever resolved and serum CRP decreased to <1 mg/dL. Subsequently, PSL was tapered gradually to 1.5, 1.0, and 0.5 mg/kg/day every 5-7 days, maintaining a continuous decrease in serum CRP. PSL was discontinued if serum CRP remained within the normal range (<0.2 mg/dL) on the 0.5 mg/kg/day PSL dose. PSL was given orally once the patient's conditions improved.
The protocol for the second study was designed to estimate the efficacy of the intensified regimen of co-administration of PSL and a second dose of IVIG (Fig. 1) . The intensified regimen was used for patients resistant to the first dose of IVIG and who had high serum CRP (≥10 mg/dL) after the first IVIG dose (high CRP group).
All patients were treated with 30 mg/kg aspirin during the febrile phase, followed by 5 mg/kg aspirin after the fever subsided.
Efficacy
The effect of the first IVIG dose was estimated according to the course of fever 48 h after initiation of IVIG. IVIG was considered to be effective if body temperature (BT) was confirmed to be <37.5°C on at least two consecutive vital sign examinations, usually at 6-8 h intervals. In this case, the therapy was judged to be effective and no treatment was added thereafter. IVIG was considered to be ineffective if BT was persistently >38.0°C; in this case, the therapy was judged to be ineffective and the second IVIG treatment was started. The effects of IVIG were considered to be indeterminable if BT was not persistently higher than 38.0°C but did not met the criteria of "effective". In this case, BT measurements were repeated daily until a decision was made. If the effect of IVIG was still indeterminable at 96 h after initiation of IVIG, the therapy was judged to be ineffective and the second IVIG treatment was started.
The effect of second-and third-line therapy was judged in the same way.
Statistical analysis
Mann-Whitney U-test was used to estimate the significance of differences, while the significance of incidence was estimated using Fisher's exact test. The significance of the relationship of the clinical and laboratory findings to the effectiveness of the second IVIG dose was estimated on multivariate logistic regression analysis. All analysis was carried out using STATA 13 (Light Stone, Tokyo, Japan). 
Results
Subjects
A total of 621 subjects participated in the first study, and 466 participated in the second study (Table 1) . There were no significant differences in sex ratio; ratio of the number of patients who met five diagnostic criteria to that who met six; age at onset; or the number of days from diagnosis to the initiation of IVIG between the subjects in the first and second studies.
First study
Effect of PSL
The first dose of IVIG was effective in 474 out of 621 patients (76.3%) ( Table 2 ). The second dose of IVIG was effective in 99 out of 147 subjects (67.3%). The cumulative efficacy was 92.3%. Thirty-nine out of 48 subjects resistant to the second dose of IVIG were treated with PSL as third-line therapy, and PSL was effective in 34 of the subjects (87.2%). PEX 12 was used in five subjects and was effective in four subjects (80.0%), while a third dose of IVIG was given to four subjects and was effective in one subject (25.0%).
Incidence of CAL
Persistent CAL was seen in 2.1% of subjects in the first study, while the rate of giant aneurysm was 0.3% (Table 3 ). The rate of persistent CAL was significantly higher in patients resistant to than in patients responsive to the second dose of IVIG (18.8% vs 3.0%, P < 0.01). Reinforcement of the second-line therapy for subjects resistant to the first dose of IVIG is indispensable for reducing the incidence of persistent CAL.
Prediction of second IVIG dose ineffectiveness
We previously reported that subjects resistant to the second dose of IVIG had significantly higher serum CRP after the first dose of IVIG than those who responded to the second dose of IVIG. 13 To confirm this, the following data were used in multivariate logistic regression analysis: age, sex, number of criteria met by the subject, Harada score, number of days after diagnosis to the initiation of the first dose of IVIG, serum CRP, white blood cell (WBC) count, and serum IgG (Table 4) . Laboratory data from both before and after the first IVIG treatment were included. Serum CRP level after the first dose of IVIG alone was proven to be useful for distinguishing patients resistant to the second dose of IVIG (z-value = 2.20, P = 0.028).
High serum CRP after the first IVIG dose
To confirm the results of multivariate logistic regression analysis, patients resistant to the first dose of IVIG were divided into two groups according to serum CRP level after the first dose of IVIG: the high CRP group (CRP ≥ 10 mg/dL), and the low CRP group (CRP < 10 mg/dL).
The effectiveness of the second dose of IVIG in the high CRP group was significantly lower than in the low CRP group (47.8% vs 76.8%, P < 0.005; Table 5 ). The rates of persistent CAL (19.6% vs 3.0%, P < 0.005) and giant aneurysm (4.3% vs 0.0%) were also higher in the high CRP group than in the low CRP group. Interestingly, however, the response to PSL as third-line therapy was not different between the two groups (88.9% vs 85.7%; Table 5 ).
Second study
Effectiveness of the intensified regimen
In the second study, the intensified regimen consisting of the co-administration of PSL with the second dose of IVIG was applied in 34 high CRP group subjects (intensified regimen group 1, IG-1; Fig. 1 ). This regimen was also applied to 10 subjects resistant to the first dose of IVIG who had serum CRP <10 mg/dL after the first IVIG dose (median, 7.3 mg/dL; range, 5.0-9.7 mg/dL; intensified regimen group 2, IG-2; Table 2 ). Given that IG-2 deviated from the protocol, analysis was focused on IG-1.
Total effectiveness of second-line therapy in the second study was significantly higher than in the first study (81.3% vs 67.3%, P < 0.05; Table 2 ). The effectiveness of the intensified regimen in IG-1 was 79.4%, similar to that in the low CRP group treated with the second dose of IVIG alone (83.3%; Fig. 2a ).
Persistent CAL
The incidence of CAL in the second study was 1.3% (6/466, including one case of giant aneurysm), which was lower than in the first study (2.1%, 13/621; including two cases of giant aneurysm), although the difference was not significant (Table 3) . In the second study, the incidence of persistent CAL in IG-1 was 8.8% (3/34), and that in IG-2 was 0.0% (0/10). Although the incidence of persistent CAL in IG-1 was higher than in the low CRP group treated with the second IVIG dose alone (2.4%, 2/84), the difference was not significant (Fig. 2b) , in contrast to the first study.
PSL treatment
The percentage of patients treated with PSL at the third step in the first study was 6.3% (39/621), while that at the second step in the second study was 9.4% (44/466).
Adverse events
There were no reports of adverse reactions to PSL. With regard to IVIG, the following adverse effects were reported: aseptic meningitis (n = 2), hemolytic anemia (n = 1), hives (n = 3), and eruption (n = 1). All these complications were transient, and the subjects recovered without sequelae.
Discussion
The number of KD patients has been increasing over the past few decades. 1, 4 CAL is the best-known and most serious complication of KD, with a risk of lethal outcome. The incidence of CAL has been dramatically reduced by introducing IVIG into the KD treatment regimen KD. 2, 3 Presently, IVIG is widely accepted as the first-line therapy for KD, 1 but approximately 20% of patients are resistant to IVIG. In Japan, an additional IVIG dose is the most popular regimen for patients resistant to the first dose of IVIG. 4 The second dose of IVIG, however, is reported to be less effective than the first. [5] [6] [7] In the first of the present large-scale prospective multicenter studies, the efficacy of the second dose of IVIG was 67.3%, a little lower than that of the first dose (76.3%). This agrees with our previous report involving 224 subjects. 14 Thus, although the efficacy of the second dose of IVIG is a little lower than that of the first, it seems to be useful as a second-line therapy for KD.
In the first of the present studies, we also estimated the efficacy of the third-line regimens. Currently, in addition to PSL, [8] [9] [10] [11] steroid pulse therapy, 7,15 PEX, 12 cyclosporine A (CyA), 16 and infliximab (IFX) 17, 18 are used for the treatment of severe KD. In the first of the present studies, PSL, PEX, CyA, and additional IVIG could be chosen as third-line treatment. Among them, PSL was a predominantly popular regimen; it was used in 34 of 39 subjects requiring third-line treatment (Table 2) . It also had excellent effectiveness in the treatment of KD resistant to two consecutive IVIG doses (87.2%).
As was reported previously, 6, 7 we also confirmed in the first of the present studies that the incidence of persistent CAL increases markedly in KD patients resistant to the second dose of IVIG. If those KD patients can be identified prior to the second dose of IVIG, then prognosis could be improved with reinforced second-step therapy. We previously reported that high serum CRP after the first IVIG dose may be a useful indicator of resistance to the second dose of IVIG. 13 This immunoglobulin (IVIG) dose. In the first study, both the high and low CRP groups were treated with the second dose of IVIG. In contrast, in the second study, the high CRP group was treated with the intensified regimen consisting of prednisolone (PSL) plus the second dose of IVIG (intensified regimen group 1), while the low CRP group was treated with the second dose of IVIG alone. **P < 0.01.
assumption was again confirmed in the present study with a larger number of subjects. Some investigators also noted the usefulness of serum CRP after the first IVIG dose in predicting outcome of IVIG-resistant KD. Mori et al. showed that increased serum CRP and neutrophils after the first IVIG dose are related to an increase in the incidence of CAL, 19 but they did not analyze the efficacy of the second-line therapy.
Recently, Nakagama et al. reported that persistent fever and increased CRP after the first IVIG dose are useful for predicting unresponsiveness to the second-line therapy. 20 In their study, however, the sample size was small and the regimen used in the second step was not specified. In the first of the present studies, the second-line therapy was limited to a second dose of IVIG. Under these conditions, we showed that the unresponsiveness to the second dose of IVIG can be predicted simply by serum CRP level after the first IVIG dose (Table 4) .
Based on this result, subjects were classified into two groups according to serum CRP after the first IVIG dose: the high (≥10 mg/dL) and low (<10 mg/dL) CRP groups. The cutoff CRP level of 10 mg/dL was set because of simplicity, although it is a little higher than that indicated on receiver operating characteristic (ROC) curve analysis (8.89 mg/dL; sensitivity, 58.3%; specificity, 73.0%). The effectiveness of the second IVIG dose in the high CRP group was significantly lower than in the low CRP group (Table 5) . Moreover, the incidence of CAL and giant aneurysm was higher in the high CRP group than in the low CRP group. This indicates the necessity for a reinforced second-line therapy to improve the prognosis of the high CRP group.
Because the efficacy of PSL in the high CRP group at the third step was similar to that in the low CRP group (Table 5) , the effect of the second IVIG dose could be enhanced with co-treatment with PSL (intensified regimen). To confirm the effect of the intensified regimen, we conducted the second study. As expected, the effectiveness of the intensified regimen in the high CRP group was remarkably greater than that of IVIG alone in the first study (Fig. 2a) , and resulted in apparent reduction of the incidence of persistent CAL (Fig. 2b) .
Recently, PSL co-treatment with the first dose of IVIG was proposed for patients who are estimated to be resistant to IVIG on a specific scoring system. 21 More than 30% of subjects are expected to be treated with PSL in this protocol. A pilot study (RAISE study) showed the efficacy of first dose IVIG plus PSL in reducing inflammation in severe KD, compared with IVIG alone. 9 The precision of the scoring system used to predict the resistance to the first dose of IVIG, however, was not high. 22, 23 A considerable number of subjects who may respond to the first dose of IVIG would be treated with PSL unnecessarily.
Although the beneficial effect of PSL seems to be increasingly accepted, physicians must avoid unnecessary use because of undesirable side-effects. 24 In the second of the present studies, PSL was used after confirming unresponsiveness to the first dose of IVIG. Moreover, the subjects were limited to those in the high CRP group. Thus, the percentage of patients treated with PSL in the second of the present studies was as low as 9.4%, approximately one-third of that in the RAISE study.
Kobayashi et al. also reported on the usefulness of PSL cotreatment with a second dose of IVIG in KD patients resistant to the first dose of IVIG. 25 In that study, however, all subjects resistant to the first dose of IVIG were treated with PSL without any stratification. The second of the present studies, however, shows that the use of PSL could be reduced by using serum CRP level after the first IVIG dose to identify the highrisk group.
The incidence of persistent CAL in the second of the present studies is lower than the average in Japan (1.3% vs 2.8%), 4 and does not appear to be higher than that in studies in which PSL is co-administered with IVIG in the first or second step of therapy. Although the results of each study cannot be compared directly, the protocol used in the second of the present studies may be worthy of further investigation, because it could be a useful option for patients and physicians wanting to avoid unnecessary use of PSL.
